STE on NYSE

Steris

Logo: Steris, Public domain, via Wikimedia Commons5

Irish registered American medical device company

Steris plc is an American-Irish-based medical equipment company specializing in sterilization and surgical products for the US healthcare system. Steris is operationally headquartered in Mentor, Ohio, and has been legally registered in Dublin, Ireland, for tax purposes since 2018. Previously the company was registered in the United Kingdom from 2014 to 2018.3 Wikipedia text CC BY-SA 4.0

Price unavailable

Last updated Oct 21, 2026.

Overview

$5.9BRevenue, fiscal 20266
$782.3MNet income, fiscal 20266
1985Founded1

Compare with Edwards Lifesciences, Zimmer Biomet Holdings or Align Technology, or pick any stock.

  • TickerSTE on NYSE1
  • Industryhealth care industry1
  • HeadquartersIreland1
  • Websitewww.steris.com
  • Legal formprivate company limited by shares, public limited company1
  • Incorporated inIreland7
  • Business address70 Sir John Rogerson'S Quay, Dublin, L2 27
  • Filer categoryLarge accelerated filer7
  • LEI549300AFNA4MU52671374
  • StatusActive4
  • LEI statusIssued and current4
  • Registered addressC/O CT CORPORATION SYSTEM, 43219 Columbus, United States4
  • Registered withCorporation Database (Ohio Secretary of State), 6602234

Steris plc is an American-Irish-based medical equipment company specializing in sterilization and surgical products for the US healthcare system. Steris is operationally headquartered in Mentor, Ohio, and has been legally registered in Dublin, Ireland, for tax purposes since 2018. Previously the company was registered in the United Kingdom from 2014 to 2018.3

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2026

44.2%Gross margin6
18.6%Operating margin6
13.2%Net margin6
8.7%Revenue growth, 20266
10.9%Return on equity6
0.25×Debt to equity6
$972.4MFree cash flow6

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

Product brought in 52% of the revenue Steris broke down this way in fiscal 2026.

  1. Product$3.1B652%up 7% from 2025
  2. Service$2.9B648%up 11% from 2025
Products and services by year
Products and services202420252026
Product$2.8B$2.9B$3.1B
Service$2.4B$2.6B$2.9B

Business segments

Healthcare brought in 71% of the revenue Steris broke down this way in fiscal 2026.

  1. Healthcare$4.2B671%up 9% from 2025
  2. Applied Sterilization Technologies$1.1B619%up 10% from 2025
  3. Life Science$588.8M610%up 9% from 2025
Business segments by year
Business segments202420252026
Healthcare$3.6B$3.9B$4.2B
Applied Sterilization Technologies$954.0M$1.0B$1.1B
Life Science$571.7M$542.3M$588.8M

Regions

United States brought in 73% of the revenue Steris broke down this way in fiscal 2026.

  1. United States$4.3B673%up 8% from 2025
  2. Other foreign locations$1.5B625%up 11% from 2025
  3. Ireland$108.5M62%up 1% from 2025
Regions by year
Regions202420252026
United States$3.8B$4.0B$4.3B
Other foreign locations$1.3B$1.3B$1.5B
Ireland$82.7M$107.3M$108.5M

Where the money goes

Where each dollar of revenue went, fiscal 2026

  • Cost of revenue56¢$3.3B
  • Research and development2¢$112.9M
  • Selling, general and admin24¢$1.4B
  • Other costs1¢$61.4M
  • Income tax4¢$262.2M
  • Profit13¢$782.3M

Out of $5.9B in revenue.6

Where each dollar of operating cash went, fiscal 2026

  • Capital spending28¢$369.0M
  • Dividends paid18¢$241.8M
  • Share buybacks18¢$235.5M
  • Kept or used elsewhere37¢$495.1M

Out of $1.3B of cash from operations.6

Financial statements

Revenue10111213146$5.9B in 2026+113% since 2019
0$2.0B$4.0B$6.0B2019: $2.8B$2.8B20192020: $3.0B$3.0B2020+9%2021: $3.1B$3.1B2021+3%2022: $4.2B$4.2B2022+36%2023: $4.5B$4.5B2023+7%2024: $5.1B$5.1B2024+13%2025: $5.5B$5.5B2025+6%2026: $5.9B$5.9B2026+9%
Gross profit10111213146$2.6B in 2026+124% since 2019
0$1.0B$2.0B$3.0B2019: $1.2B$1.2B20192020: $1.3B$1.3B2020+12%2021: $1.3B$1.3B2021+2%2022: $1.9B$1.9B2022+40%2023: $2.0B$2.0B2023+5%2024: $2.2B$2.2B2024+12%2025: $2.4B$2.4B2025+8%2026: $2.6B$2.6B2026+9%
Operating income10111213146$1.1B in 2026+168% since 2019
0$500.0M$1.0B$1.5B2019: $411.0M$411.0M20192020: $537.0M$537.0M2020+31%2021: $548.4M$548.4M2021+2%2022: $477.8M$477.8M2022−13%2023: $791.1M$791.1M2023+66%2024: $836.1M$836.1M2024+6%2025: $866.6M$866.6M2025+4%2026: $1.1B$1.1B2026+27%
Net income10111213146$782.3M in 2026+158% since 2019
0$200.0M$400.0M$600.0M$800.0M2019: $303.7M$303.7M20192020: $407.7M$407.7M2020+34%2021: $397.4M$397.4M2021−3%2022: $243.9M$243.9M2022−39%2023: $107.0M$107.0M2023−56%2024: $378.2M$378.2M2024+253%2025: $614.6M$614.6M2025+63%2026: $782.3M$782.3M2026+27%

Every line of the income statement as filed: the last 3 fiscal years, latest first.6

Period ending2026-03-312025-03-312024-03-31
Total revenues$5.9B$5.5B$5.1B
Cost of revenues$3.3B$3.1B$2.9B
Gross Profit$2.6B$2.4B$2.2B
Selling, general, and administrative$1.4B$1.3B$1.3B
Research and development$112.9M$107.6M$103.7M
Litigation Settlement, Loss$0$48.2M$0
Restructuring Costs$4.1M$46.0M$26.0M
Total operating expenses$1.5B$1.5B$1.4B
Income (loss) from operations$1.1B$866.6M$836.1M
Interest expense$60.7M$86.3M$144.4M
Interest income and miscellaneous expense-$9.8M-$8.4M-$11.0M
Other expense (income), net-$3.5M$7.4M$0
Total non-operating expenses, net$54.4M$70.4M$133.3M
Income (loss) before income tax expense (benefit)$1.0B$796.2M$702.8M
Income tax expense (benefit)$262.2M$184.7M$149.5M
Income from continuing operations, net of income tax$785.1M$611.6M$553.3M
Income (loss) from discontinued operations, net of income tax$0$4.5M-$173.2M
Net income$785.1M$616.1M$380.1M
Less: Net income attributable to noncontrolling interests$2.8M$1.4M$1.8M
Net income attributable to shareholders$782.3M$614.6M$378.2M
Income (Loss) from Continuing Operations, Per Basic Share$8$6$6
Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share$0$0-$2
Earnings Per Share, Basic$7.97$6.24$3.83
Income (Loss) from Continuing Operations, Per Diluted Share$8$6$6
Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share$0$0-$2
Earnings Per Share, Diluted$7.93$6.20$3.81
Cash dividends declared per common share outstanding$2.46$2.23$2.03

Compare Steris with another company

Corporate structure

Steris sits at the top of its group. 152 entities, 36 countries on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Steris

  • Steris Columbus, Ohio, United States
    • Albert Browne Limited Subsidiary · United Kingdom
    • American Sterilizer Company Subsidiary · Pennsylvania, United States
    • Bioster-Mottahedoon Egypt SAE Subsidiary · Egypt
    • Birkova Products, LLC Subsidiary · Indiana, United States
    • Bizworth Gammarad Sdn Bhd Subsidiary · Malaysia
    • Black Diamond Video, Inc. Subsidiary · California, United States
    • Cantel (Belgium) BV Subsidiary · Belgium
    • Cantel (UK) Limited Subsidiary · United Kingdom
    • Cantel Medical (UK) Limited Subsidiary · United Kingdom
    • Cantel Medical Asia/Pacific Pte. Ltd. Subsidiary · Singapore
    • Cantel Medical Devices (China) Co., Ltd. Subsidiary · China
    • Cantel Medical International B.V. Subsidiary · Netherlands
    • Cantel Medical LLC Subsidiary · Delaware, United States
    • CLBV Limited Subsidiary · United Kingdom
    • Diagmed Healthcare Limited Subsidiary · United Kingdom
    • Electron Beam Sdn. Bhd. Subsidiary · Malaysia
    • Eschmann Holdings Limited Subsidiary · United Kingdom
    • Genii, Inc. Subsidiary · Minnesota, United States
    • GEST PROHS, LDA Subsidiary · Portugal
    • Harwell Dosimeters Limited Subsidiary · United Kingdom
    • Herotron E-Beam Service GmbH Subsidiary · Germany
    • HMM HoldCo Limited Subsidiary · United Kingdom
    • Hungaroptics KFT Subsidiary · Hungary
    • IK Medical Solutions GmbH Subsidiary · Germany
    • Isomedix Inc. Subsidiary · Delaware, United States
    • and 126 more

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; subsidiaries, stakes and holdings from Wikidata (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Steris reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Land$112.3M6 Mar 31, 2026$106.1M6 Mar 31, 2025+5.8%
Buildings and improvements$903.6M6 Mar 31, 2026$832.1M6 Mar 31, 2025+8.6%
Machinery and equipment$1.4B6 Mar 31, 2026$1.2B6 Mar 31, 2025+19.0%
Construction in progress$509.5M6 Mar 31, 2026$512.1M6 Mar 31, 2025−0.5%
Property and equipment, before depreciation$4.1B6 Mar 31, 2026$3.7B6 Mar 31, 2025+11.3%
Accumulated depreciation$1.9B6 Mar 31, 2026$1.7B6 Mar 31, 2025+12.3%
Property and equipment, net$2.2B6 Mar 31, 2026$2.0B6 Mar 31, 2025+10.5%
Operating-lease assets (leased space)$155.2M6 Mar 31, 2026$156.4M6 Mar 31, 2025−0.8%

Intangibles and goodwill

ItemLatestA year beforeChange
Goodwill$4.2B6 Mar 31, 2026$4.1B6 Mar 31, 2025+2.4%
Intangible assets, net (excluding goodwill)$1.6B6 Mar 31, 2026$1.9B6 Mar 31, 2025−12.6%
Indefinite-lived intangibles (excluding goodwill)$14.3M6 Mar 31, 2026$14.3M6 Mar 31, 20250%
Finite-lived intangibles, gross$3.4B6 Mar 31, 2026$3.4B6 Mar 31, 2025+1.2%
Accumulated amortization$1.8B6 Mar 31, 2026$1.5B6 Mar 31, 2025+18.2%

Inventory

ItemLatestA year beforeChange
Inventory, total$631.8M6 Mar 31, 2026$581.3M6 Mar 31, 2025+8.7%
Raw materials$225.4M6 Mar 31, 2026$213.1M6 Mar 31, 2025+5.8%
Work in process$90.7M6 Mar 31, 2026$83.1M6 Mar 31, 2025+9.1%
Finished goods$355.2M6 Mar 31, 2026$334.9M6 Mar 31, 2025+6.1%

Properties, in its own words

The following discussion sets forth materially important properties of the Company and its subsidiaries as of March 31, 2026. The Company believes that its facilities are adequate for operations and are maintained in good condition. The Company is confident that, if needed, it will be able to acquire additional facilities at commercially reasonable rates.

The Company’s principal executive office is located in Dublin, Ireland and its primary administrative offices are located in Mentor, OH (U.S.).

The rest of Item 2

In our AST segment, we operate over 60 owned or leased facilities dedicated to delivering contract sterilization services. These strategically positioned locations are situated near Customer manufacturing and distribution sites, as well as key distribution corridors across Africa, Asia, Europe, and North America.

The Company operates approximately 250 locations representing sales, administrative, manufacturing and operational locations in the U.S. and more than 35 other countries, the majority of which are leased and support one or multiple business segments. In addition to these locations, the Company partners with third-party logistics service providers to streamline the distribution of product and materials. Operational locations are primarily comprised of service centers, manufacturing and distribution warehouses. Our locations are geographically spread to be in close proximity to our Customers to ensure timely delivery of products and services.

Included among totals listed above, the Company owns and leases manufacturing facilities that support the Healthcare, Life Sciences, and AST segments. The locations we deem to be material are disclosed in the following table:

Location · Owned/Leased

Conroe, TX · Owned

Guadalupe, Mexico · Owned

Mentor, OH · Owned/Leased

Montgomery, AL · Owned/Leased

Plymouth, MN · Owned/Leased

Quebec City, Canada · Owned

St. Louis, MO · Owned/Leased

Leicester, England · Owned

Ottawa, Canada · Leased

Point Richmond, CA · Leased

Tuusula, Finland · Owned

Pomezia, Italy · Owned

Bishop's Stortford, England · Leased

Franklin Park, IL · Leased

Sharon Hill, PA · Owned

Tuttlingen, Germany · Leased

Item 2 of the 10-K filed May 29, 2026.19

The story

Steris was founded in August 1985 in Ohio, under the name "Innovative Medical Technologies".

In 2012, Steris acquired US Endoscopy for $270 million. Steris also acquired Spectrum Surgical Instruments Corp. and Total Repair Express for $110 million combined.

On April 1, 2014, Steris announced its acquisition of Integrated Medical Systems International Inc. for ~$175 million, although it would only cost the company ~$140 million after tax benefits. Shortly after, Steris also acquired Chesterfield, Missouri-based Life Systems.

In October 2014, Steris executed a tax inversion from the United States to the United Kingdom, via an offer made to acquire UK-based Synergy Health for $1.9 billion. The tax inversion was notable as it was the first US inversion post the new rules introduced by the Obama administration in 2014 to curb US corporations moving their "legal domicile" to reduce their exposure to US corporate taxation.

On June 24, 2015, Steris announced the acquisitions of General Econopak for $175 million and Black Diamond Video for $51 million.

Steris filed accounts which showed global revenues of over US$2.6 billion in 2018, of which US$1.8 billion (or 70 percent) came from the US healthcare system; and employed ~12,000 people.

In November 2018, Steris announced that it would further re-domicile its legal headquarters from the United Kingdom to Ireland; Steris had reduced its corporate tax rate from 31.3 percent to 20 percent as a result of its 2014 tax inversion to the United Kingdom, however, it believed a further reduction could be achieved by moving to Ireland.

In April 2020, Steris received emergency use authorization from the FDA for a N95 mask sterilization system to help address the shortage of personal protective equipment during the 2019-20 coronavirus pandemic.

Read the full text

In November 2020, Steris acquired Key Surgical, a leading global provider of sterile processing, operating room, and endoscopy products.

In June 2021, Steris acquired Cantel Medical Corporation a provider of infection prevention products and services to endoscopy, dental and dialysis.

From Wikipedia’s article on Steris, shared under CC BY-SA 4.0.8

Leadership

Who has led Steris, and when. Pick a name to see everywhere that person has worked.

Board members and other officers (28)

Subsidiaries and ownership

Subsidiaries

  • Steris (France)
  • Steris (United Kingdom)

Subsidiaries (Exhibit 21)

  • Albert Browne Limited England and Wales9
  • American Sterilizer Company Pennsylvania, USA9
  • Bioster-Mottahedoon Egypt SAE Egypt9
  • Birkova Products, LLC Indiana, USA9
  • Bizworth Gammarad Sdn Bhd Malaysia9
  • Black Diamond Video, Inc. California, USA9
  • CLBV Limited England and Wales9
  • Cantel (Belgium) BV Belgium9
  • Cantel (UK) Limited England and Wales9
  • Cantel Medical (UK) Limited England and Wales9
  • Cantel Medical Asia/Pacific Pte. Ltd. Singapore9
  • Cantel Medical Devices (China) Co., Ltd. China9
  • Cantel Medical International B.V. Netherlands9
  • Cantel Medical LLC Delaware, USA9
  • Diagmed Healthcare Limited England and Wales9
  • Electron Beam Sdn. Bhd. Malaysia9
  • Eschmann Holdings Limited England and Wales9
  • GEST PROHS, LDA Portugal9
  • Genii, Inc. Minnesota, USA9
  • HMM HoldCo Limited England and Wales9
  • Harwell Dosimeters Limited England and Wales9
  • Herotron E-Beam Service GmbH Germany9
  • Hungaroptics KFT Hungary9
  • IK Medical Solutions GmbH Germany9
All 159 listed subsidiaries
  • Isomedix Inc. Delaware, USA9
  • Isomedix Operations Inc. Delaware, USA9
  • Jet Prep Ltd. Israel9
  • José Dos Santos Monteiro Lda. Portugal9
  • KVI LLC Delaware, USA9
  • KWI Planung GmbH Germany9
  • Key Surgical Europe S.à r.l. Switzerland9
  • Key Surgical LLC Delaware, USA9
  • Key Surgical Limited England and Wales9
  • Konnexis Inc. Canada9
  • MEDIK Hospital Design GmbH Germany9
  • MEDIK Hospital Design Memmingen GmbH Germany9
  • MEDIK Hospital Design SWISS AG Switzerland9
  • Mar Cor Purification, Inc. Pennsylvania, USA9
  • Massaro Limited Partnership (Victory Road) Pennsylvania, USA9
  • Medi-Cart International Limited England and Wales9
  • Medical Innovations Group Holdings Limited England and Wales9
  • Medical Innovations Group Ltd England and Wales9
  • Medisafe America, L.L.C. Florida, USA9
  • Medisafe Holdings Ltd England and Wales9
  • Medisafe UK Limited England and Wales9
  • Medivators Inc. Minnesota, USA9
  • Mevex Corporation Canada9
  • PROHS – Equipamento Hospitalar e Serviços Associados, S.A. Portugal9
  • STE UK HoldCo Limited England and Wales9
  • STE UK Sub HoldCo Limited England and Wales9
  • STERILMED France France9
  • STERIS (BVI) I Limited British Virgin Islands9
  • STERIS (India) Private Limited India9
  • STERIS (Shanghai) Trading Co., Ltd. China9
  • STERIS AB Sweden9
  • STERIS AST CZ s.r.o. Czech Republic9
  • STERIS AST, storitve v zdravstvu, d.o.o Slovenia9
  • STERIS Applied Sterilization Technologies ULC Canada9
  • STERIS Asia Pacific, Inc. Delaware, USA9
  • STERIS Australia PTY LTD Australia9
  • STERIS Barrier Products Solutions, Inc. Pennsylvania, USA9
  • STERIS Bethpage Processing, LLC New York9
  • STERIS Brazil Holdings, LLC Delaware, USA9
  • STERIS CH Limited England and Wales9
  • STERIS Canada Sales ULC Canada9
  • STERIS Canada ULC Canada9
  • STERIS China Holdings Limited Hong Kong9
  • STERIS Colombia S.A.S Colombia9
  • STERIS Corporation Ohio, USA9
  • STERIS Corporation de Costa Rica, S.A. Costa Rica9
  • STERIS Corporation de Republica Dominicana, S.R.L. Dominican Republic9
  • STERIS Deutschland GmbH Germany9
  • STERIS Dover AST Holdings Limited England and Wales9
  • STERIS Dover Canada Holdings Limited England and Wales9
  • STERIS Dover Limited England and Wales9
  • STERIS Emerald IE Limited Ireland9
  • STERIS Europe, Inc. Delaware, USA9
  • STERIS FinCo II S.à r.l. Luxembourg9
  • STERIS FinCo S.à r.l. Luxembourg9
  • STERIS GmbH Switzerland9
  • STERIS Holdings B.V. Netherlands9
  • STERIS Hong Kong Limited Hong Kong9
  • STERIS IMS Canada Inc. Canada9
  • STERIS IMS Limited England and Wales9
  • STERIS Iberia,S.A. Spain9
  • STERIS Inc. Delaware, USA9
  • STERIS Instrument Management Services, Inc. Delaware, USA9
  • STERIS Ireland Limited Ireland9
  • STERIS Irish FinCo II Unlimited Company Ireland9
  • STERIS Irish FinCo Unlimited Company Ireland9
  • STERIS Isomedix Puerto Rico LLC Puerto Rico9
  • STERIS Israel Solutions Ltd Israel9
  • STERIS Italy S.r.l. Italy9
  • STERIS Japan Inc. Japan9
  • STERIS Laboratories, Inc. Minnesota, USA9
  • STERIS Latin America, Inc. Delaware, USA9
  • STERIS Limited England and Wales9
  • STERIS Luxembourg Finance S.à r.l. Luxembourg9
  • STERIS Luxembourg Holding S.à r.l. Luxembourg9
  • STERIS Malaysia SDN. BHD. Malaysia9
  • STERIS Mexico, S. de R.L. de C.V. Mexico9
  • STERIS Netherlands B.V. Netherlands9
  • STERIS New Zealand Limited New Zealand9
  • STERIS Personnel Services, Inc. Delaware, USA9
  • STERIS Portugal, Unipessoal, Lda. Portugal9
  • STERIS S.p.A. Italy9
  • STERIS S.r.l. Italy9
  • STERIS SA Belgium9
  • STERIS SAS France9
  • STERIS Schweiz AG Switzerland9
  • STERIS Solutions Korea Limited South Korea9
  • STERIS Solutions Limited England and Wales9
  • STERIS Solutions Pte. Limited Singapore9
  • STERIS Solutions do Brasil Importacao e Comercializacao de Produtos da Saude Ltda. Brazil9
  • STERIS Solutions, S. de R.L. de C.V. Mexico9
  • STERIS Sterilization Technologies (Suzhou) Ltd. China9
  • STERIS TOMOE (Thailand) Ltd. Thailand9
  • STERIS Taiwan Co., Ltd. Taiwan9
  • STERIS Tomoe Singapore Pte. Ltd Singapore9
  • STERIS UK Holding Limited England and Wales9
  • STERIS US Holdings Corp. Delaware, USA9
  • STERIS-SHINVA Healthcare Systems Co., Ltd. China9
  • Shamrock Innovations Limited Ireland9
  • Shiloh Limited England and Wales9
  • Solar New US Holding Corporation Delaware, USA9
  • Solar New US Parent Co, LLC Delaware, USA9
  • Solar US Acquisition Co, LLC Delaware, USA9
  • Sterile Supplies Limited England and Wales9
  • Synergy Health (Thailand) Limited Thailand9
  • Synergy Health (UK) Limited England and Wales9
  • Synergy Health AST S.r.l. Costa Rica9
  • Synergy Health AST, LLC Delaware, USA9
  • Synergy Health Allershausen GmbH Germany9
  • Synergy Health Amsterdam B.V. Netherlands9
  • Synergy Health Ede B.V. Netherlands9
  • Synergy Health Holding B.V. Netherlands9
  • Synergy Health Holdings Limited England and Wales9
  • Synergy Health Investments Limited England and Wales9
  • Synergy Health Ireland Limited Ireland9
  • Synergy Health Limited England and Wales9
  • Synergy Health Logistics B.V. Netherlands9
  • Synergy Health Marseille SAS France9
  • Synergy Health Nederland B.V. Netherlands9
  • Synergy Health Radeberg GmbH Germany9
  • Synergy Health Sterilisation UK Limited England and Wales9
  • Synergy Health Systems Limited England and Wales9
  • Synergy Health US Holdings, Inc. Delaware, USA9
  • Synergy Health Westport Limited Ireland9
  • Synergy Sterilisation (M) Sdn Bhd Malaysia9
  • Synergy Sterilisation KL (M) Sdn Bhd Malaysia9
  • Synergy Sterilisation Kulim (M) Sdn Bhd Malaysia9
  • Synergy Sterilisation Rawang (M) Sdn Bhd Malaysia9
  • Synergy Sterilisation South Africa (Propietary) Limited South Africa9
  • TECNOPROS – Comércio e Assistência Técnica, Lda Portugal9
  • TekGo, Inc. Delaware, USA9
  • The STERIS Foundation Ohio, USA9
  • United States Endoscopy Group, Inc. Ohio, USA9
  • Vernon and Co. Limited England and Wales9
  • Vernon-Carus Limited England and Wales9

From Wikidata.1 The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.

Former names

  • STERIS LtdNov 6, 2018 to Mar 28, 20197

Timeline

  1. Oct 13, 20268-K Entered a material agreement50
  2. Aug 6, 20268-K Executive or director change51
  3. Aug 6, 20268-K Shareholder vote52
  4. Aug 5, 20268-K Results of operations; Exit or restructuring costs53
  5. May 11, 20268-K Results of operations54
  6. May 7, 20268-K Executive or director change; Regulation FD disclosure55
  7. Apr 6, 20268-K Executive or director change56
  8. Feb 4, 20268-K Results of operations57
  9. Nov 5, 20258-K Results of operations58
  10. Aug 6, 20258-K Results of operations; Executive or director change; Shareholder vote59
  11. Jul 3, 20258-K Executive or director change60
  12. May 14, 20258-K Results of operations61
  13. Jun 2, 2022New chief executive Daniel A. Carestio becomes CEO20
  14. Mar 27, 2019New chief executive Walter M. Rosebrough Jr. becomes CEO21
  15. Jun 1, 1992Went public Listed on NYSE1
  16. 1985Founded Founded1

Calendar

Coming up

  1. Nov 4, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported $2.47 a share, on Nov 5, 2025.62

When it reported results

  1. Aug 5, 2026Reported quarterly or annual results53
  2. May 11, 2026Reported quarterly or annual results54
  3. Feb 4, 2026Reported quarterly or annual results57
  4. Nov 5, 2025Reported quarterly or annual results58
  5. Aug 6, 2025Reported quarterly or annual results59
  6. May 14, 2025Reported quarterly or annual results61
  7. Feb 5, 2025Reported quarterly or annual results63
  8. Nov 6, 2024Reported quarterly or annual results64

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

403 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 39 major events, 259 insider forms, 19 large holders, 66 other. The latest 20:

  1. Oct 13, 20268-K EDGAR
  2. Oct 5, 20264 EDGAR
  3. Aug 18, 2026144 EDGAR
  4. Aug 12, 2026144 EDGAR
  5. Aug 12, 20264 EDGAR
  6. Aug 12, 20264 EDGAR
  7. Aug 12, 20264 EDGAR
  8. Aug 12, 20264 EDGAR
  9. Aug 12, 20264 EDGAR
  10. Aug 12, 20264 EDGAR
  11. Aug 12, 20264 EDGAR
  12. Aug 12, 20264 EDGAR
  13. Aug 7, 202610-Q EDGAR
  14. Aug 6, 20268-K EDGAR
  15. Aug 6, 20268-K/A EDGAR
  16. Aug 5, 20268-K EDGAR
  17. Jul 2, 20264 EDGAR
  18. Jun 16, 202611-K EDGAR
  19. Jun 16, 20264 EDGAR
  20. Jun 15, 2026144 EDGAR

The 403 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

48 open-market trades by officers, directors and large owners since October 2021: 0 buys and 48 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Aug 12, 2026Sohi MohsenDirectorSale4,058$235.78$956.8KForm 4
Jun 15, 2026Zangerle John AdamSr. VP, Gen Counsel, and Sec.Sale1,419$209.28$297.0KForm 4
Jun 5, 2026Carestio Daniel APresident and CEOSale1,374$212.00$291.3KForm 4
Jun 4, 2026Carestio Daniel APresident and CEOSale3,054$214.64$655.5KForm 4
Jun 2, 2026Breeden Richard CDirectorSale1,481$209.51$310.3KForm 4
Mar 5, 2026FELDMANN CYNTHIA LDirectorSale3,098$237.21$734.9KForm 4
Nov 21, 2025Madsen JuliaSr. VP and GM, Life SciencesSale5,008$262.00$1.3MForm 4
Nov 18, 2025Tamaro RenatoV.P. & Corporate TreasurerSale5,036$257.55$1.3MForm 4
Nov 11, 2025Zangerle John AdamSr. VP, Gen Counsel, and Sec.Sale15,000$265.14$4.0MForm 4
Oct 6, 2025Carestio Daniel APresident and CEOSale159$241.82$38.4KForm 4
Aug 20, 2025Tamaro RenatoV.P. & Corporate TreasurerSale3,204$249.24$798.6KForm 4
Aug 11, 2025Sohi MohsenDirectorSale4,110$241.96$994.5KForm 4
Aug 11, 2025FELDMANN CYNTHIA LDirectorSale3,495$241.56$844.3KForm 4
Aug 11, 2025Burton Karen LSr. Vice Pres., CFOSale7,900$241.73$1.9MForm 4
Jun 13, 2025Zangerle John AdamSr. VP, Gen Counsel, and Sec.Sale1,978$241.45$477.6KForm 4
Jun 5, 2025Carestio Daniel APresident and CEOSale17,626$242.56$4.3MForm 4
May 20, 2025Majors Cary LSVP and President, HealthcareSale12,828$250.08$3.2MForm 4
Nov 25, 2024Majors Cary LSVP and President, HealthcareSale1,682$217.32$365.5KForm 4
Sep 16, 2024TOKICH MICHAEL JSr. Vice Pres., CFOSale20,213$244.45$4.9MForm 4
Sep 13, 2024TOKICH MICHAEL JSr. Vice Pres., CFOSale3,119$248.02$773.6KForm 4

All 48 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2026President and CEO$1.1M$11.5M72
2026Senior Vice Presidentand Chief Financial Officer$530.8K$3.2M72
2026Senior Financial Advisor$511.4K$2.2M72
2025President and CEO$1.1M$10.7M72
2025Senior Financial Advisor$633.5K$3.3M72
2025Senior Vice PresidentGeneral Counsel, and Company Secretary$553.5K$2.9M72
2024President and CEO$1.0M$9.6M72
2024Senior Financial Advisor$613.8K$3.2M72
2024Senior Vice PresidentGeneral Counsel, and Company Secretary$536.5K$2.6M72

Members of Congress who traded it

22 trades disclosed by members of Congress. “Vs S&P since” is the stock’s change since the trade minus the S&P 500’s.

DateMemberTradeAmountVs S&P sinceFiling
Sep 15, 2026Kevin HernRepublican, HouseSale$15,001 - $50,000−4.8%Report
Aug 25, 2026April McClain DelaneyDemocratic, HouseSale$100,001 - $250,000+5.9%Report
Jul 31, 2026April McClain DelaneyDemocratic, HousePartial sale$1,001 - $15,000+5.1%Report
Jul 29, 2026April McClain DelaneyDemocratic, HousePartial sale$1,001 - $15,000+10.3%Report
Jul 27, 2026April McClain DelaneyDemocratic, HousePartial sale$1,001 - $15,000+1.7%Report
Jul 24, 2026April McClain DelaneyDemocratic, HousePartial sale$1,001 - $15,000−0.3%Report
Jul 13, 2026Jared MoskowitzDemocratic, HouseSale$1,001 - $15,000−0.3%Report
May 13, 2026Gilbert Ray Cisneros, Jr.Democratic, HouseBuy$1,001 - $15,000+2.3%Report
May 11, 2026Gilbert Ray Cisneros, Jr.Democratic, HouseBuy$1,001 - $15,000+6.7%Report
May 1, 2026Gilbert Ray Cisneros, Jr.Democratic, HouseBuy$1,001 - $15,000−2.5%Report
Apr 30, 2026April McClain DelaneyDemocratic, HouseBuy$1,001 - $15,000−4.0%Report
Apr 29, 2026Gilbert Ray Cisneros, Jr.Democratic, HouseBuy$1,001 - $15,000−3.0%Report
Mar 16, 2026April McClain DelaneyDemocratic, HouseBuy$1,001 - $15,000−12.9%Report
Feb 10, 2026Gilbert Ray Cisneros, Jr.Democratic, HouseBuy$1,001 - $15,000−19.8%Report
Feb 6, 2026April McClain DelaneyDemocratic, HouseBuy$1,001 - $15,000−22.8%Report
Sep 18, 2025April McClain DelaneyDemocratic, HouseBuy$1,001 - $15,000−27.0%Report
Sep 11, 2025April McClain DelaneyDemocratic, HouseBuy$1,001 - $15,000−28.5%Report
Jun 26, 2025April McClain DelaneyDemocratic, HousePartial sale$1,001 - $15,000+32.1%Report
Feb 25, 2025Robert P. Bresnahan, Jr.Republican, HouseBuy$1,001 - $15,000−29.6%Report
Jul 14, 2023Jared MoskowitzDemocratic, HouseBuy$1,001 - $15,000−73.9%Report
Mar 18, 2020Gilbert Ray Cisneros, Jr.Democratic, HouseBuy$1,001 - $15,000−138.9%Report
Jun 24, 2019Donna Shalala, HouseSale$1,001 - $15,000+108.4%Report

Members report amounts as ranges, not exact figures. Returns are price-only (no dividends).

SEC filer profile

How Steris is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARSTERIS plc2
  • CIK0001757898
  • Employer ID (EIN)98-145506419
  • Filer statusLarge accelerated filer not an emerging growth company; not a smaller reporting company; not a shell company19
  • Incorporated inIreland19
  • Fiscal year endsMarch 312
  • Industry code (SIC)3842 Orthopedic, Prosthetic & Surgical Appliances & Supplies2
  • SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance2
  • Business address70 Sir John Rogerson'S Quay, Dublin, L2 22
  • Phone353123220002
  • Shares outstanding97,500,110 as of Aug 4, 202617
  • Public float$24.2B as of Sep 30, 202519
  • AuditorErnst & Young LLP, Cleveland, Ohio PCAOB ID 42; it also attests to the company’s internal control over financial reporting19
  • On EDGAR sinceNov 6, 20182
  • Filings680 in all: 4 (408), 8-K (60), 144 (36), 3 (32), 10-Q (22), SC 13G/A (17), 425 (12), DEFA14A (9)2
    All 33 form types

    10-K (8), 11-K (8), DEF 14A (8), SD (8), 4/A (7), 8-K/A (4), ARS (4), UPLOAD (4), CORRESP (3), S-8 (3), SC 13G (3), SCHEDULE 13G (3), 424B3 (2), 424B5 (2), 8-A12B (2), CERT (2), S-4 (2), S-4/A (2), S-4MEF (2), SCHEDULE 13G/A (2), 3/A (1), EFFECT (1), FWP (1), S-3ASR (1), SC 13D (1)

  • Latest filingsAnnual report (10-K) May 29, 2026
    Quarterly report (10-Q) Aug 7, 2026
    Proxy statement (DEF 14A) Jun 11, 2026
    Latest 8-K (8-K) Oct 13, 2026

Securities registered for trading

ClassSymbolExchange
Ordinary Shares, $0.001 par valueSTENew York Stock Exchange
2.700% Senior Notes due 2031STE/31New York Stock Exchange
3.750% Senior Notes due 2051STE/51New York Stock Exchange

From the cover page of the 10-K filed May 29, 2026 (Section 12(b) of the Exchange Act).19

Risk factors and legal proceedings

The risks Steris names in Item 1A of its 10-K filed May 29, 2026: 33 risks under these headings, as written.19

  • LEGAL, REGULATORY AND TAX RISKS
  • Doing Business Internationally
  • Changes in economic climate may adversely affect us.
  • The effects of geopolitical instability may adversely affect us and create significant risks and uncertainties for our business, with the ultimate impact dependent on future developments, which are highly uncertain and unpredictable.
  • Compliance with multiple, and potentially conflicting, international laws and regulations, import and export limitations, anti-corruption laws, and exchange controls may be difficult, burdensome or expensive.
  • Healthcare Policy and Reimbursement
  • Changes in healthcare policy or government and other third-party payor reimbursement levels to healthcare providers, or failure to meet healthcare reimbursement or other requirements, might negatively impact our business.
  • Product and Service Related Regulations and Claims
  • We are subject to extensive regulatory requirements and must receive and maintain regulatory clearance or approval for many products and operations. Failure to receive or maintain, or delays in receiving, clearance or approvals may negatively impact our revenues, profitability, financial condition, or value.
  • Our products are subject to recalls and restrictions, even after receiving U.S. or foreign regulatory clearance or approval.
  • We may be adversely affected by product liability claims or other legal actions or regulatory or compliance matters.
  • Our business and financial condition could be adversely affected by difficulties in acquiring or maintaining a proprietary intellectual ownership position.
The other 24 risks
  • We may be adversely impacted by changes in tax laws or challenges to our tax positions, and our effective tax rate is uncertain and may vary from expectations, which could have a material impact on our results of operations and earnings per share.
  • Current economic and political conditions make tax rules in any jurisdiction subject to significant change.
  • Changes in tax treaties and trade agreements could negatively impact our costs, results of operations and earnings per share.
  • Legislation relating to the denial of U.S. federal or state governmental contracts to U.S. companies that redomicile abroad could adversely affect our business.
  • BUSINESS AND OPERATIONAL RISKS
  • Our business environment is highly competitive, and if we fail to compete successfully, our revenues and results of operations may be negatively impacted.
  • Consolidations among our healthcare and pharmaceutical Customers may result in a loss of Customers or more significant pricing pressures.
  • Supply chain disruption might increase our production costs, limit our production capabilities or curtail our operations.
  • Our operations, and those of our suppliers, are subject to a variety of business continuity hazards and risks, any of which could interrupt production or operations or otherwise adversely affect our performance, results, or value.
  • Expectations relating to corporate responsibility considerations expose us to potential liabilities, increased costs, reputational harm and other adverse effects on our business.
  • We may be adversely affected by global climate change or by existing and future legal, regulatory or market responses to such change.
  • Our operations are subject to regulations and permitting, which may be changed or amended by the relevant authorities, and which may limit or eliminate our current operations or increase the complexity, burden, or expense of compliance, and regulated materials or processes that we use in our operations are, and may in the future become subject to litigation.
  • Our EO sterilization operations subject us to claims of liability and associated adverse effects.
  • If our continuing efforts to create a Lean business, to in-source production and to support smart manufacturing to reduce costs are not successful, our profitability may be negatively impacted or our business otherwise might be adversely affected.
  • A pandemic or similar public health crisis could have a material adverse impact on our ability to staff our operations.
  • Our business and results of operations may be adversely affected if we are unable to recruit and retain qualified management and other personnel.
  • We could experience a failure of a key information technology system, process or site or a breach of information security, including a cybersecurity breach of one or more key information technology systems, networks, processes, associated sites or service providers; failure to manage these and other risks associated with the use of sophisticated technology could materially impact our business.
  • Our debt level or access to credit markets may limit our financial and business flexibility.
  • RISKS RELATED TO BUSINESS DEVELOPMENT
  • We engage in acquisitions and affiliations, divestitures, and other business arrangements. Our growth may be adversely affected if we are unable to successfully identify and price strategic business candidates or otherwise optimize our business portfolio.
  • Our investments in our business and product offerings may not be as successful as anticipated.
  • Our business realignment initiatives may not be as successful as anticipated.
  • Our acquisition activity and ability to grow organically may be adversely affected if we are unable to continue to access the financial markets.
  • The integration of acquired businesses into STERIS or working arrangements with joint venture partners may not be as successful as anticipated.
  • STERIS has incurred and expects to incur significant transaction and related costs in connection with strategic transactions, which may be in excess of those anticipated.
  • We have recorded goodwill and other intangible assets that could become impaired and result in material non-cash charges to our results of operation in the future.

Legal proceedings

Information regarding our legal proceedings is included in Item 7 of Part II, Management's Discussion and Analysis, and Note 12 to our consolidated financial statements titled, "Commitments and Contingencies," and is incorporated herein by reference thereto.

The opening of Item 3, Legal Proceedings.19

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65
  66. 66
  67. 67
  68. 68
  69. 69
  70. 70
  71. 71
  72. 72